| Size | Price | |
|---|---|---|
| 1mg | ||
| Other Sizes |
| Targets |
50-C2-C9-4tail does not have a defined pharmacological target; it is a formulation component. It is an ionizable lipid that facilitates the encapsulation of nucleic acids (siRNA, mRNA) into LNPs. At low pH (e.g., within endosomes), it becomes positively charged, promoting electrostatic interaction with negatively charged nucleic acids and enabling endosomal escape after cellular uptake. At physiological pH, it is neutral, which reduces toxicity. Its primary mechanism of action is to enhance the delivery of nucleic acid cargo into target cells.
|
|---|---|
| ln Vitro |
50-C2-C9-4tail has been used in the generation of LNPs for the delivery of siRNA and mRNA in vitro. LNPs formulated with 50-C2-C9-4tail demonstrate efficient encapsulation of nucleic acids, protection from RNase degradation, and successful transfection of various cell lines, leading to gene silencing (siRNA) or protein expression (mRNA). The lipid is designed to promote cellular uptake and endosomal escape, enabling the therapeutic nucleic acid to reach its site of action in the cytoplasm. It is a key component for developing LNP-based gene therapies.
|
| ln Vivo |
50-C2-C9-4tail has been used in the generation of LNPs for the delivery of siRNA and mRNA in vivo in animal models. LNPs containing 50-C2-C9-4tail can be administered via intravenous injection, leading to efficient delivery of nucleic acid cargo to target tissues such as the liver and spleen. The LNPs protect the nucleic acids from degradation, prolong circulation time, and facilitate cellular uptake and endosomal escape, enabling robust protein expression (from mRNA) or gene silencing (from siRNA). This lipid is a research tool for developing LNP-based vaccines and therapeutics.
|
| Enzyme Assay |
For LNP formulation, 50-C2-C9-4tail is typically mixed with helper lipids (e.g., cholesterol, DSPC, and PEG-lipid) in organic solvent (ethanol) at defined molar ratios (e.g., 50-C2-C9-4tail : cholesterol : DSPC : PEG-lipid = 50:38.5:10:1.5). The lipid mixture is combined with an aqueous solution containing nucleic acid (siRNA or mRNA) using a microfluidic device at a controlled flow rate, resulting in LNP formation. The LNPs are dialyzed against PBS to remove ethanol and concentrated. Particle size (typically 60-150 nm), polydispersity index, and zeta potential are measured by dynamic light scattering (DLS). Encapsulation efficiency is determined by RiboGreen assay.
|
| Cell Assay |
For in vitro studies, LNPs are added to cells (e.g., HEK293, HeLa, primary hepatocytes) in culture media. For mRNA delivery, reporter gene expression (e.g., luciferase, GFP) is measured after 24-48 hours. For siRNA delivery, target gene knockdown is assessed by qPCR or Western blot after 48-72 hours. Cytotoxicity is assessed by MTT assay.
|
| Animal Protocol |
For in vivo studies, 50-C2-C9-4tail-based LNPs are formulated to encapsulate siRNA or mRNA, then diluted in PBS or 10% sucrose. LNPs are administered to rodents via intravenous injection (tail vein) at doses of 0.1-5 mg/kg (based on nucleic acid content). For mRNA delivery, blood and tissues are collected to measure protein expression by bioluminescence imaging (e.g., luciferase) or ELISA. For siRNA delivery, target gene knockdown in tissues (e.g., liver) is assessed by qPCR or Western blot. Biodistribution of LNPs is assessed by measuring fluorescence (if labeled) or quantifying nucleic acid content in organs (liver, spleen, lungs) by qPCR.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for 50-C2-C9-4tail itself are not available. The molecular weight is 1594.49, and the molecular formula is C100H176N4O10. The compound is a lipid and is soluble in organic solvents such as ethanol and DMSO. For in vivo use, it is always formulated into LNPs. The half-life of 50-C2-C9-4tail-containing LNPs in circulation is determined by the LNP composition (e.g., presence of PEG). Typically, LNPs have a circulation half-life of 2-6 hours in rodents. The compound should be stored at -20degC as a solution or powder, protected from moisture and light.
|
| Toxicity/Toxicokinetics |
Toxicological data for 50-C2-C9-4tail alone are limited. As an ionizable lipid, it is expected to be well tolerated at the concentrations used in LNP formulations. In cell-based assays, LNPs containing 50-C2-C9-4tail show minimal cytotoxicity at transfection-effective concentrations. In animal studies, LNP administration may cause transient elevation of liver enzymes (ALT/AST) and pro-inflammatory cytokines at higher doses. Comprehensive toxicology studies are formulation-dependent.
|
| References | |
| Additional Infomation |
50-C2-C9-4tail is a research-grade lipid and is not approved for clinical use. It is an ionizable lipid used specifically for LNP formulation for the delivery of siRNA and mRNA. Its structure includes a piperazine core and multiple ester linkages, which are designed to enhance biodegradability. The CAS number is 1853203-01-6. Store at -20degC, protected from light and moisture.
|
| Exact Mass |
1594.342
|
|---|---|
| CAS # |
1853203-01-6
|
| PubChem CID |
118631066
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
90
|
| Heavy Atom Count |
114
|
| Complexity |
2160
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCC/C=C\\C/C=C\\CCCCCCCC(=O)OCCCCN(CCCCOC(=O)CCCCCCC/C=C\\C/C=C\\CCCCC)CCCCC1NC(=O)C(NC1=O)CCCCN(CCCCOC(=O)CCCCCCC/C=C\\C/C=C\\CCCCC)CCCCOC(=O)CCCCCCC/C=C\\C/C=C\\CCCCC
|
| InChi Key |
ZQXDXCNSODVUPG-RGLFHLPNSA-N
|
| InChi Code |
InChI=1S/C100H176N4O10/c1-5-9-13-17-21-25-29-33-37-41-45-49-53-57-61-79-95(105)111-89-73-69-85-103(86-70-74-90-112-96(106)80-62-58-54-50-46-42-38-34-30-26-22-18-14-10-6-2)83-67-65-77-93-99(109)102-94(100(110)101-93)78-66-68-84-104(87-71-75-91-113-97(107)81-63-59-55-51-47-43-39-35-31-27-23-19-15-11-7-3)88-72-76-92-114-98(108)82-64-60-56-52-48-44-40-36-32-28-24-20-16-12-8-4/h21-28,33-40,93-94H,5-20,29-32,41-92H2,1-4H3,(H,101,110)(H,102,109)/b25-21-,26-22-,27-23-,28-24-,37-33-,38-34-,39-35-,40-36-
|
| Chemical Name |
4-[4-[5-[4-[bis[4-[(9Z,12Z)-octadeca-9,12-dienoyl]oxybutyl]amino]butyl]-3,6-dioxopiperazin-2-yl]butyl-[4-[(9Z,12Z)-octadeca-9,12-dienoyl]oxybutyl]amino]butyl (9Z,12Z)-octadeca-9,12-dienoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
